A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
← catalyst calendarNCT07566897 · readout ≤ 1,230 d
Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
96estimated
Sites
1
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-01 | estimated | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Renal Carcinoma Metastatic
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Metastatic Colorectal Carcinoma (mCRC)
Interventions
- Drug: L19IL2
- Drug: Ruxolitinib
Primary outcomes
what the primary-completion date above is the date OFSTEP A and STEP B: DLT
measured From Day 1 to Day 28 of the treatment
Safety (AE)
measured Through study completion, an average of 1 year
Safety (SAEs)
measured Through study completion, an average of 1 year
Safety (DILI)
measured Through study completion, an average of 1 year
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed